Condition
Tumors With CDK4/6 Pathway Activation
Estimated Enrollment: 106
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: CLEE011XUS03
Study First Received: July 9, 2014
Last Updated: November 27, 2016
Estimated Primary Completion Date: April 2018
Primary Outcome Measures:
Clinical benefit rate associated with LEE011 treatment|Overall Response (OR) of Partial Response (PR) or greater|Progression Free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)|Safety and tolerability
Sponsors and Collaborators:
Novartis Pharmaceuticals|Novartis
Website Link: https://ClinicalTrials.gov/show/NCT02187783
